title: Ocular Findings in Alemtuzumab (Campath-1H)-induced Thyroid Eye Disease.
abstract: Alemtuzumab (Campath-1H) is a humanized anti-CD52 monoclonal antibody used in the treatment of multiple sclerosis (MS). Studies demonstrate significant reduction in relapse risk and the risk of accumulating sustained disability. Adverse events include infusion-associated reactions, infections, and secondary autoimmunity. Systemic thyroid disease is the most common secondary autoimmune event and affects up to approximately 30% of treated patients. This is the first description of the ocular findings and management in a case of thyroid eye disease (Graves' Ophthalmopathy [GO]) following alemtuzumab therapy. The ocular disease was managed conservatively while the systemic Graves' was managed with thyroidectomy.
authors: †Department of Surgery, University of Queensland; and ‡Department of Ophthalmology, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
authors: Tanya
authors: T
authors: Trinh
authors: Anjana S
authors: AS
authors: Haridas
authors: Timothy J
authors: TJ
authors: Sullivan
mesh_terms: D000328:Adult; D000074323:Alemtuzumab; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects; D005260:Female; D049970:Graves Ophthalmopathy / Q000139:chemically induced / Q000175:diagnosis*; D006801:Humans; D013961:Thyroid Gland / Q000000981:diagnostic imaging*; D014057:Tomography, X-Ray Computed
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000074323:Alemtuzumab